After completing this course, the reader will be able to:1. List the top 10 ranked symptoms after discharge suffered by patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) treatment.2. Identify the significant factors in the associations between quality of life (QOL) and demographic factors and clinical factors over a period of 2 months in patients with HCC receiving TACE.3. Design individualized education programs for newly diagnosed and recurrent HCC patients in order to maintain better QOL after treatment.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME
ABSTRACTObjective. To (a) explore changes in physical and psychological distress and quality of life (QOL) and (b) identify the significant pre-and postdischarge factors related to changes in physical and mental domains of QOL over a period of 2 months in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization (TACE) treatment. Methods. A longitudinal prospective design was used, with participants recruited from a teaching hospital in Northern Taiwan. Data were collected three times: within 3 days prior to discharge (T0) and at the fourth (T1) and eighth (T2) weeks after discharge. A set of structured questionnaires was used to assess participants' QOL, symptom distress, anxiety, and depression. Changes in QOL and associated factors were examined using generalized estimating equations.Results. Eighty-nine patients were included in this study. Fatigue was reported to be the most distressful symptom after treatment. Overall QOL improved monthly after discharge.